UBS maintained its Buy rating on a major pharmaceutical company after a series of clinical trial failures and merger speculation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE